<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT201207244333N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2012-08-30</date_registration>
      <primary_sponsor>Noor eye hospital</primary_sponsor>
      <public_title>New treatment of keratoconus with UV</public_title>
      <acronym></acronym>
      <scientific_title>comparison of 30 minutes and 5 minutes collagen cross-linking in patients with keratoconus</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2012-08-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/4612</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Keratoconus.</hc_freetext>
      <i_freetext>Intervention 1: Intervention name: 5 min-UV radiation in corneal cross-linking&#13;
Intervention description: After local anesthesia with Proparacaine hydrochloride 0.5% eye drop, 3 or 4 vertical strips about 2 mm wide remove from the central 8-9 mm corneal epithelium. Then, riboflavin 0.1% drop in dextra 20% is instilled onto the cornea every 3 minutes for half an hour (a total of 10 times). At the end of this stage, the patient is examined by the slit lamp to ensure the presence of riboflavin and yellow tindall in the anterior chamber. Then, ultraviolet irradiation at a wavelength of 370 nanometer, a width of 9 mm, power 3mW/cm2 and a distance of 5cm is started. In interventional group, Ultraviolet irradiation is continued for 5 minutes.  At the end of irradiation, the corneal surface is rinsed with sterile balanced saline solution, a soft bandage contact lens was placed. Chloramphenicol and betamethasone eye drop will be prescribed at discharge. Intervention 2: The control intervention: 30 min-UV radiation in corneal cross-linking (routin treatment)&#13;
Control intervention description: After local anesthesia with Proparacaine hydrochloride 0.5% eye drop, 3 or 4 vertical strips about 2 mm wide remove from the central 8-9 mm corneal epithelium. Then, riboflavin 0.1% drop in dextra 20% is instilled onto the cornea every 3 minutes for half an hour (a total of 10 times). At the end of this stage, the patient is examined by the slit lamp to ensure the presence of riboflavin and yellow tindall in the anterior chamber. Then, ultraviolet irradiation at a wavelength of 370 nanometer, a width of 9 mm, power 3mW/cm2 and a distance of 5cm is started. In control group, Ultraviolet irradiation is continued for 30 minutes.  At the end of irradiation, the corneal surface is rinsed with sterile balanced saline solution, a soft bandage contact lens was placed. Chloramphenicol and betamethasone eye drop will be prescribed at discharge.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Soheila Asgari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>#96 Esfandiar Blvd., Vali’asr Ave.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1968653111</zip>
        <telephone>+98 21 8240 1621</telephone>
        <email>soheilaasgari@gmail.com</email>
        <affiliation>Noor eye hospital</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hassan Hashemi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>#96 Esfandiar Blvd., Vali’asr Ave.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1968653111</zip>
        <telephone>+98 21 8865 1515</telephone>
        <email>hhashemi@noorvision.com</email>
        <affiliation>Noor ophthalmology research center, Noor eye hospital</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>inclusion criteria: keratometry less than 60 diopter; central corneal thickness of 400 microns or more; keratoconus progression in the past 12 months documented as at least one D increase in maximum keratometry, or manifest cylinder; Bilateral surgery&#13;
Exclusion criteria: diabetes and other systematic disease; use of corticosteroid and immunosupressive drugs in the past 6 months</inclusion_criteria>
      <agemin>15 years</agemin>
      <agemax>35 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>H18.6</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>keratoconus</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention name: 5 min-UV radiation in corneal cross-linking&#13;
Intervention description: After local anesthesia with Proparacaine hydrochloride 0.5% eye drop, 3 or 4 vertical strips about 2 mm wide remove from the central 8-9 mm corneal epithelium. Then, riboflavin 0.1% drop in dextra 20% is instilled onto the cornea every 3 minutes for half an hour (a total of 10 times). At the end of this stage, the patient is examined by the slit lamp to ensure the presence of riboflavin and yellow tindall in the anterior chamber. Then, ultraviolet irradiation at a wavelength of 370 nanometer, a width of 9 mm, power 3mW/cm2 and a distance of 5cm is started. In interventional group, Ultraviolet irradiation is continued for 5 minutes.  At the end of irradiation, the corneal surface is rinsed with sterile balanced saline solution, a soft bandage contact lens was placed. Chloramphenicol and betamethasone eye drop will be prescribed at discharge.</i_keyword>
      <i_keyword>The control intervention: 30 min-UV radiation in corneal cross-linking (routin treatment)&#13;
Control intervention description: After local anesthesia with Proparacaine hydrochloride 0.5% eye drop, 3 or 4 vertical strips about 2 mm wide remove from the central 8-9 mm corneal epithelium. Then, riboflavin 0.1% drop in dextra 20% is instilled onto the cornea every 3 minutes for half an hour (a total of 10 times). At the end of this stage, the patient is examined by the slit lamp to ensure the presence of riboflavin and yellow tindall in the anterior chamber. Then, ultraviolet irradiation at a wavelength of 370 nanometer, a width of 9 mm, power 3mW/cm2 and a distance of 5cm is started. In control group, Ultraviolet irradiation is continued for 30 minutes.  At the end of irradiation, the corneal surface is rinsed with sterile balanced saline solution, a soft bandage contact lens was placed. Chloramphenicol and betamethasone eye drop will be prescribed at discharge.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Corneal biomechanical assay. Timepoint: pre op, 1m, 3m and 6m after surgery. Method of measurement: Cornea status is evaluated by Ocular Response Analyzer (ORA), confoscan, and endothelial cell count (ECC).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Refraction. Timepoint: pre op, 1m, 3m and 6m after surgery. Method of measurement: autorefractometer.</sec_outcome>
      <sec_outcome>Keratometry. Timepoint: pre op, 1m, 3m and 6m after surgery. Method of measurement: Pentacam.</sec_outcome>
      <sec_outcome>Visual acuity. Timepoint: pre op, 1m, 3m and 6m after surgery. Method of measurement: Snellen chart.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Noor eye hospital</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2012-07-26</approval_date>
        <contact_name>Noor eye hospital</contact_name>
        <contact_address>#96 Esfandiar Blvd., Vali’asr Ave. Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
